124 related articles for article (PubMed ID: 6498336)
1. Coagulation Factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models.
Menache D; Behre HE; Orthner CL; Nunez H; Anderson HD; Triantaphyllopoulos DC; Kosow DP
Blood; 1984 Dec; 64(6):1220-7. PubMed ID: 6498336
[TBL] [Abstract][Full Text] [Related]
2. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
[TBL] [Abstract][Full Text] [Related]
3. Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals.
Smith KJ
Blood; 1988 Oct; 72(4):1269-77. PubMed ID: 3262386
[TBL] [Abstract][Full Text] [Related]
4. Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma.
Michalski C; Bal F; Burnouf T; Goudemand M
Vox Sang; 1988; 55(4):202-10. PubMed ID: 3265237
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
Prowse CV; Williams AE
Thromb Haemost; 1980 Oct; 44(2):81-6. PubMed ID: 6779401
[TBL] [Abstract][Full Text] [Related]
6. Preparation and properties of a therapeutic factor IX concentrate.
Suomela H; Myllylä G; Raaska E
Vox Sang; 1977 Jul; 33(1):37-50. PubMed ID: 883244
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and thrombogenicity of factor IX concentrate.
Sakuragawa N; Takahashi K; Itoh M; Matsuoka M
Bibl Haematol; 1977; 44():88-93. PubMed ID: 617788
[TBL] [Abstract][Full Text] [Related]
8. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography.
Burnouf T; Michalski C; Goudemand M; Huart JJ
Vox Sang; 1989; 57(4):225-32. PubMed ID: 2617959
[TBL] [Abstract][Full Text] [Related]
9. Purification of human factor IX by chromatography of a coagulation factor concentrate.
Suomela H
Thromb Haemost; 1976 Feb; 35(1):211-21. PubMed ID: 989188
[TBL] [Abstract][Full Text] [Related]
10. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
11. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo.
White GC; Roberts HR; Kingdon HS; Lundblad RL
Blood; 1977 Feb; 49(2):159-70. PubMed ID: 12845
[TBL] [Abstract][Full Text] [Related]
12. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Santagostino E; Tradati FC; Rosenberg RD
Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
[TBL] [Abstract][Full Text] [Related]
13. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates.
Kim HC; McMillan CW; White GC; Bergman GE; Horton MW; Saidi P
Blood; 1992 Feb; 79(3):568-75. PubMed ID: 1531035
[TBL] [Abstract][Full Text] [Related]
14. The preparation of the factors IX, II, and X concentrate by means of DEAE cellulos and its therapeutic effectiveness.
Uszyński L; Poszwiński P
Folia Haematol Int Mag Klin Morphol Blutforsch; 1975; 102(5):591-4. PubMed ID: 54310
[TBL] [Abstract][Full Text] [Related]
15. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
McLaughlin LF; Drummond O; MacGregor IR
Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
[TBL] [Abstract][Full Text] [Related]
16. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Bottasso B; Simoni L; Rosenberg RD
Blood; 1990 Dec; 76(12):2540-5. PubMed ID: 2265248
[TBL] [Abstract][Full Text] [Related]
17. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity.
Gray E; Tubbs J; Thomas S; Oates A; Boisclair M; Kemball-Cook G; Barrowcliffe TW
Thromb Haemost; 1995 Apr; 73(4):675-9. PubMed ID: 7495077
[TBL] [Abstract][Full Text] [Related]
18. Coagulation factor IX: successful surgical experience with a purified factor IX concentrate.
Goldsmith JC; Kasper CK; Blatt PM; Gomperts ED; Kessler CM; Thompson AR; Herring SW; Novak PL
Am J Hematol; 1992 Jul; 40(3):210-5. PubMed ID: 1609775
[TBL] [Abstract][Full Text] [Related]
19. [Preparation and clinical use of a new factor IX concentrate].
Lopaciuk S; Poszwiński P
Acta Haematol Pol; 1978; 9(2):107-12. PubMed ID: 665130
[TBL] [Abstract][Full Text] [Related]
20. Some properties of autoprothrombin II-A anticoagulant.
Emekli NB; Ulutin ON
Bibl Haematol; 1977; 44():15-20. PubMed ID: 617778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]